Evidence map›Paper›PMID 39638432›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

[

Joanna K Weeks, Austin R Pantel, Sarah B Gitto, Fang Liu, Erin K Schubert, Daniel A Pryma, Michael D Farwell, David A Mankoff, Robert H Mach, Fiona Simpkins and 1 more

Erratum issuedAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Dual-receptor PET imaging of ovarian cancer using aAmerican journal of nuclear medicine and molecular imaging · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Joanna K WeeksDivision of Interventional Radiology, Department of Radiology, Weill Cornell Medicine, New York, New York.
Austin R PantelDivision of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Sarah B GittoDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Fang LiuDepartment of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Erin K SchubertDivision of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Daniel A PrymaDivision of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Michael D FarwellDivision of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
David A MankoffDivision of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Robert H MachDivision of Nuclear Medicine Imaging and Therapy, Department of Radiology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
Fiona SimpkinsDivision of Gynecologic Oncology, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; and.
Lilie L LinDepartment of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas lllin@mdanderson.org.

Funding

A novel PARP inhibitor PET tracer for breast cancerR01CA249329 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI LIN, LILIE LEMING, PIWNICA-WORMS, DAVID · 2021 to 2023
$748k
NCI NIH HHS R01 CA249329
6 · The paper itself

Abstract

Poly(adenosine diphosphate-ribose) polymerase-1 (PARP1) inhibitors have improved ovarian cancer treatment outcomes. However, clinical response remains heterogeneous. Existing biomarkers, mainly breast cancer susceptibility genes 1 and 2 (

Indexed as

Fluorodeoxyglucose F18MutationNeoplasm GradingOvarian NeoplasmsPositron-Emission TomographyAdultAgedBreast NeoplasmsFemaleHumansMiddle AgedFluorodeoxyglucose F18[18F]fluorthanatrace[18F]FTTBRCAovarian cancerPARP1

Identifiers

PMID39638432
PMCPMC13671396

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.